EU Accelerated Assessment Tracker
BioMarin has secured accelerated assessment at the European Medicines Agency for the planned filing of its potential new gene therapy for severe hemophilia A, Valrox. There was rejection for Amarin's Vascepa. The outcomes of more than a handful of other fast-track requests that companies have made for their planned or recent marketing authorization applications are still unknown.
You may also be interested in...
Just one of four accelerated assessment requests that were decided on at the European Medicines Agency this month is known to have been granted – for BioMarin’s Valrox. There was rejection for Amarin; Roche and Orchard are keeping the outcomes to themselves.
Seven new products, including the world’s first ever Ebola vaccine, are on track to receive EU-wide approval. Meanwhile, two drugs have failed to make the grade.
Amarin’s cardiovascular risk reducing drug, Vascepa, is among four new products being considered for accelerated assessment by the European Medicines Agency.